The inverse association of cancer and Alzheimer's: A bioenergetic mechanism

Journal of the Royal Society Interface

Volumn 10, Issue 82, 2013, Pages

  Demetrius, Lloyd A ^a,b   Simon, David K ^c  

^a HARVARD UNIVERSITY   (United States)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Glycolysis; Inverse Warburg effect; Metabolic stability; Oxidative phosphorylation; Warburg effect

Indexed keywords

DISEASES; NEURONS; PATHOLOGY; PHOSPHORYLATION;

ALZHEIMER'S DISEASE; GLYCOLYSIS; METABOLIC DISORDERS; METABOLIC DYSREGULATION; METABOLIC STABILITY; OXIDATIVE PHOSPHORYLATION; THERAPEUTIC STRATEGY; WARBURG EFFECTS;

METABOLISM;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; CYTOCHROME C OXIDASE; PHOSPHATE; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; ASTROCYTE; BIOENERGY; BRAIN REGION; CANCER CELL; CATALYSIS; CELL INTERACTION; CELL MEMBRANE; CELLULAR PARAMETERS; CYTOSOL; DISEASE ASSOCIATION; ELECTROCHEMICAL ANALYSIS; ENERGY METABOLISM; ENERGY YIELD; ENTROPY; ENZYME ACTIVE SITE; EXTRACELLULAR SPACE; FERMENTATION; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; INHIBITION KINETICS; NEOPLASM; NERVE CELL; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; QUANTUM CHEMISTRY; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; THERMODYNAMICS; UPREGULATION; WARBURG EFFECT; ANIMAL; BIOLOGICAL MODEL; CELL DEATH; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; CELL DEATH; GLYCOLYSIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEURONS; OXIDATIVE PHOSPHORYLATION;

MLCS; MLOWN;

EID: 84881269890     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2013.0006     Document Type: Article

References (40)

1. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC. 2005 Alzheimer disease and cancer. Neurology 64, 895-898. (doi:10.1212/01.WNL.0000152889.94785.51)
2. Warburg O. 1956 Origin of cancer cells. Oncologia 9, 75-83. (doi:10.1159/000223920)
3. Vander Heiden MG, Cantley LC, Thompson CB. 2009 Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033. (doi:10.1126/science.1160809)
4. Seyfried TN, Shelton LM. 2010 Cancer as a metabolic disease. Nutr. Metab. 7, 7. (doi:10.1186/1743-7075-7-7)
5. Hanahan D, Weinberg RA. 2000 The hallmarks of cancer. Cell 100, 57-70. (doi:10.1016/S0092-8674(00)81683-9)
6. Demetrius LA, Simon DK. 2012 An inverse-Warburg effect and the origin of Alzheimer's disease. Biogerontology 13, 583-594. (doi:10.1007/s10522-012-9403-6)
7. Lin MT, Beal MF. 2006 Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795. (doi:10.1038/nature05292)
8. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. 2010 Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim. Biophys. Acta 1802, 2-10. (doi:10.1016/j.bbadis.2009.10.006)
9. Roe CM et al. 2010 Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74, 106-112. (doi:10.1212/WNL.0b013e3181c91873)
10. Behrens MI, Lendon C, Roe CM. 2009 A common biological mechanism in cancer and Alzheimer's disease? Curr. Alzheimer Res. 6, 196-204. (doi:10.2174/156720509788486608)
11. Driver JA et al. 2012 Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. Br. Med. J. 344, e1442. (doi:10.1136/bmj.e1442)
12. Plun-Favreau H, Lewis PA, Hardy J, Miguel Martins L, Wood NW. 2010 Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet. 6, e1001257. (doi:10.1371/journal. pgen.1001257)
13. Demetrius L. 2004 Caloric restriction, metabolic rate, and entropy. J. Gerontol. 59, B902-B915. (doi:10.1093/gerona/59.9.B902)
14. Demetrius LA, Coy JF, Tuszynski J. 2010 Quantum metabolism, the Warburg effect and the proliferation of cancer. Theor. Biol. Med. Model. 7, 2. (doi:10.1186/1742-4682-7-2)
15. Hayflick L. 2007 Biological aging is no longer an unsolved problem. Ann. NY Acad. Sci. 1100, 1-13. (doi:10.1196/annals.1395.001)
16. Harold FM. 1986 A study of bioenergetics. London, UK: WH Freeman and Company.
17. Lehninger AL. 1965 Bioenergetics: the molecular basis of biological energy transformations. Biology Teaching Monograph Series. New York, NY: W. A. Benjamin.
18. Calder WA. 1983 Size, function, and life history III. Cambridge, MA: Harvard University Press.
19. Peters RH. 1983 The ecological implications of body size. Cambridge, UK: Cambridge University Press.
20. Demetrius L. 2003 Quantum statistics and allometric scaling of organisms. Physica A 322, 477-490. (doi:10.1016/S0378-4371(03)00013-X)
21. Demetrius L, Tuszynski JA. 2010 Quantum metabolism explains the allometric scaling of metabolic rates. J. R. Soc. Interface 7, 507-514. (doi:10.1098/rsif.2009.0310)
22. Demetrius L. 1997 Directionality principles in thermodynamics and evolution. Proc. Natl Acad. Sci. USA 94, 3491-3498. (doi:10.1073/pnas.94.8.3491)
23. Demetrius L, Legendre S, Harremöes P. 2009 Evolutionary entropy: a predictor of body size, metabolic rate and maximal life span. Bull. Math. Biol. 71, 800-818. (doi:10.1007/s11538-008-9382-6)
24. Pellerin L. 2008 Brain energetics (thought needs food). Curr. Opin. Clin. Nutr. Metab. Care 11, 701-705. (doi:10.1097/MCO.0b013e328312c368)
25. Fuller S, Steele M, Münch G. 2010 Activated astroglia during chronic inflammation in Alzheimer's disease: do they neglect their neurosupportive roles? Mutat. Res. 690, 40-49. (doi:10.1016/j.mrfmmm.2009.08.016)
26. Pellerin L, Bouzier-Sore A-K, Aubert A, Serres S, Merle M, Costalat R, Magistretti PJ. 2007 Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 55, 1251-1262. (doi:10.1002/glia.20528)
27. Bolaños J, Almeida A, Moncada S. 2010 Glycolysis: a bioenergetic or a survival pathway? Trends Biochem. Sci. 35, 145-149. (doi:10.1016/j.tibs.2009. 10.006)
28. Zhu X, Perry G, Moreira PI, Aliev G, Cash AD, Hirai K, Smith MA. 2006 Mitochondrial abnormalities and oxidative imbalance in Alzheimer's disease. J. Alzheimer's Dis. 9, 147-153.
29. Swerdlow RH. 2012 Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxidants Redox Signal. 16, 1434-1455. (doi:10.1089/ars.2011.4149)
30. Hardy JA, Higgins GA. 1992 Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185. (doi:10.1126/science.1566067)
31. Selkoe DJ. 1991 The molecular pathology of Alzheimer's disease. Neuron 6, 487-498. (doi:10.1016/0896-6273(91)90052-2)
32. Jhamandas JH, MacTavish D. 2004 Antagonist of the amylin receptor blocks b-amyloid toxicity in rat cholinergic basal forebrain neurons. J. Neurosci. 24, 5579-5584. (doi:10.1523/jneurosci.1051-04.2004)
33. Jhamandas JH, Li Z, Westaway D, Yang J, Jassar S, MacTavish D. 2011 Actions of b-amyloid protein on human neurons are expressed through the amylin receptor. Am. J. Pathol. 178, 140-149. (doi:10.1016/j.ajpath.2010.11.022)
34. Prins ND, Visser PJ, Scheltens P. 2010 Can novel therapeutics halt the amyloid cascade? Alzheimer's Res. Ther. 2, 3. (doi:10.1186/alzrt26)
35. Imbimbo BP, Giardina GA. 2011 γ-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr. Top. Med. Chem. 11, 1555-1570. (doi:10.2174/156802611795860942)
36. Nunomura A et al. 2001 Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767.
37. Newington JT, Pitts A, Chien A, Arseneault R, Schubert D, Cumming RC. 2011 Amyloid beta resistance in nerve cell lines is mediated by the Warburg effect. PLoS ONE 6, e19191. (doi:10.1371/journal.pone.0019191)
38. Mattson MP, Magnus T. 2006 Aging and neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci. 2, 1-13.
39. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, Morris JC, Raichle ME, Mintun MA. 2010 Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proc. Natl Acad. Sci. USA 107, 17 763-17 767. (doi:10.1073/pnas.1010461107)
40. Herrero-Mendez A, Almeida A, Fernändez E, Maestre C, Moncada S, Bolaños JP. 2009 The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat. Cell Biol. 11, 747-753. (doi:10.1038/ncb1881)